stockrowRevolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −18.0%
- Free cash flow
- −99.1%
- Total debt
- +322.7%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
Revolution Medicines, Inc. (RVMD) Book value per share
Revolution Medicines, Inc.'s book value per share at the end of fiscal 2025 was 8.6×, down 36.5% from 13.5× in fiscal 2024. At the end of the quarter to 30 September 2026 it was 11.2×. Over the past ten years it has ranged from 0.0× (fiscal 2017) to 55.0× (fiscal 2019); the current reading is higher than 44% of that period. Revolution Medicines, Inc. ranks 73rd of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 8.6× | (36.47%) |
| FY2024 | 13.5× | (16.33%) |
| FY2023 | 16.1× | 89.92% |
| FY2022 | 8.5× | 2.68% |
| FY2021 | 8.3× | (4.32%) |
| FY2020 | 8.7× | (84.27%) |
| FY2019 | 55.0× | 30.83% |
| FY2018 | 42.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 11.2× | (9.59%) |
| Jun 2026 | 12.4× | 63.22% |
| Mar 2026 | 7.6× | (11.75%) |
| Dec 2025 | 8.6× | 1.67% |
| 29 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 81.8× |
| INCY Incyte Corporation compare | 27.8× |
| RPRX Royalty Pharma PLC compare | 22.0× |
| RVMD Revolution Medicines, Inc. | 11.2× |
| GMAB Genmab A/S Sponsored ADR compare | 9.7× |
| ROIV Roivant Sciences Ltd. compare | 6.8× |
| INSM Insmed, Inc. compare | 3.3× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 0.0× |
| ARGX argenex SE compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on RVMD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement